DKCM
ALXN

Davidson Kempner Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Davidson Kempner Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-5,473,378
Closed -$1.01B – 654
2021
Q2 		$1.01B Buy
5,473,378
+1,409,202
+35% +$242M 7.81% 1
2021
Q1 		$621M Buy
4,064,176
+3,444,997
+556% +$533M 6.18% 1
2020
Q4 		$96.7M Buy
+619,179
New +$79.6M 1.13% 20
2017
Q2 		– Sell
-338,474
Closed -$41M – 201
2017
Q1 		$41M Buy
338,474
+272,508
+413% +$35.1M 0.47% 30
2016
Q4 		$8.07M Buy
+65,966
New +$8.07M 0.16% 113
2015
Q3 		– Sell
-432,378
Closed -$78.1M – 206
2015
Q2 		$78.1M Buy
+432,378
New +$74.6M 1.28% 13
2013
Q4 		– Sell
-10,000
Closed -$1.16M – 165
2013
Q3 		$1.16M Buy
+10,000
New +$1.1M 0.04% 121

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Davidson Kempner Capital Management's ALXN Position: Q3 2021 in Review

Davidson Kempner Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 5,473,378 shares — an estimated $1.01B sold.

Davidson Kempner Capital Management first reported a position in ALXN in Q3 2013 and held it in 7 quarters. The position peaked at $1.01B in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Davidson Kempner Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Davidson Kempner Capital Management sold 5,473,378 Alexion Pharmaceuticals shares in Q3 2021, an estimated $1.01B.
  • Davidson Kempner Capital Management first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 7 quarters.
  • Davidson Kempner Capital Management's Alexion Pharmaceuticals position peaked at $1.01B in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Davidson Kempner Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.